Silence Therapeutics plc
HealthcareNASDAQ:SLN · NASDAQ Global Market
+$0.01 today
Vol 0.24M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-142.2%
avg -142.2%
ROIC
-76.1%
avg -42.6%
ROA
-67.4%
avg -33.4%
Analysis
ROA is currently the strongest return metric at -67.4% versus its period average of -33.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Rhonda L. Hellums | Executive VP, CFO, Secretary & Executive Director | $512,932.00 | — | 55 | $375,000.00 | 0.79% |
Steven J. Romano | Executive Vice President and Chief Research & Development Officer | $496,667.00 | — | 67 | $300,000.00 | 0.64% |
Iain Gladstone Ross | Interim CEO & Chairman of the Board | $481,912.00 | — | 72 | $900,000.00 | 1.91% |
Marie Wikstrom Lindholm | Chief Scientific Officer | — | — | — | — | — |
Curtis Rambaran | Chief Medical Officer | — | — | — | — | — |
Jaimin Shah | SVP & General Counsel | — | — | — | — | — |
Gabriel | Chief Technical Operations Officer | — | — | — | — | — |
Gem Gokmen Hopkins | Head of IR & Corporation Communications | — | — | — | — | — |
Gianine Esposito | Chief Human Resources Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
23
$3.01M
Sells
0
$0.00
Net Sentiment
+$3.01M
Net buying
Most Active
Griffiths Richard Ian
23 transactions
1–10 of 23
Analysis
Insiders reported 23 buys worth $3.01M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3.01M. Griffiths Richard Ian was the most active insider with 23 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
Mereo BioPharma Group plc
MREO
$48.68M
Who manages SLN?
Silence Therapeutics plc (SLN) lists 9 active executives. The top listed executive is Steven J. Romano, Executive Vice President and Chief Research & Development Officer.
Are SLN insiders buying or selling?
Recent insider activity shows net buying of $20.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.